"We are initiating a process to explore alternatives available to the company to maximize stockholder value, which include ...

When I was penning my latest column for Pharma Commerce, I felt that various recent developments were worth noting, ...

AscellaHealth has announced its role as a Silver Sponsor of the World Orphan Drug Congress USA (WODC), which will convene ...

Since the Orphan Drug Act went into effect in 1983, more than 600 drugs have been approved for rare diseases, according to ...

After dropping the FNAIT therapy, Rallybio will prioritise another candidate that is being investigated in complement-driven diseases.

NX-5948 assigned the nonproprietary name "bexobrutideg"U.S. FDA Orphan Drug Designation granted to bexobrutideg for the treatment of Waldenström macroglobulinemiaAchieved $7M in milestones and a $15M ...

Glenmark's marketing portfolio as of December 2024 had 201 generic products authorised for distribution in the US. The ...

Results from Phase II studies demonstrated that rilzabrutinib showed clinically meaningful outcomes in patients with warm ...

The Latham drug pricing and market access team invites you to read this digest of recent developments on healthcare reform, the Medicaid Drug ...

Ziftomenib’s FDA application for relapsed/refractory NPM1-mutant acute myeloid leukemia is supported by data from the ...

KalVista Pharmaceuticals has licensed commercialisation rights for sebetralstat, an oral on-demand treatment for hereditary ...

AscellaHealth, a global partner delivering customizable solutions to support the specialty pharmaceutical industry, proudly ...